(2005). A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells. Proc Natl Acad Sci USA
(2006). Abastado JP: Liposomal muramyl tripeptide phosphatidylethanolamine: Targeting and activating macrophages for adjuvant treatment of osteosarcoma. Curr Cancer Drug Targets
(2002). Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res
(2008). Antiproliferative and proapoptotic activities of new pyrazolo[3,4-d]pyrimidine derivative Src kinase inhibitors in human osteosarcoma cells. Faseb J
(2008). Argyle DJ: Isolation and characterisation of cancer stem cells from canine osteosarcoma. Vet J
(2008). Choong PF: A review of clinical and molecular prognostic factors in osteosarcoma.
(2006). Comparative gene expression profiling of canine and human osteosarcoma.
(2002). Constitutive activity of signal transducer and activator of transcription 3 protein in acute myeloid leukemia blasts is associated with short disease-free survival. Blood
(2007). Coqueret O: The STAT3 oncogene as a predictive marker of drug resistance. Trends Mol Med
(2008). Cordero di Montezemolo L: In vitro antiproliferative and antimigratory activity of dasatinib in neuroblastoma and Ewing sarcoma cell lines. Oncol Rep
(1998). Crompton MR: Expression of v-src in mammary epithelial cells induces transcription via STAT3. Biochem J
(1994). Current studies of liposome muramyl tripeptide (CGP 19835A lipid) therapy for metastasis in spontaneous tumors: a progress review. J Drug Target
(2007). Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival. Cancer Res
(2005). DE: Malignant transformation but not normal cell growth depends on signal transducer and activator of transcription 3. Cancer Res
(2000). Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent. Anticancer Drug Des
(2007). Doxorubicin and BAY 12-9566 for the treatment of osteosarcoma in dogs: a randomized, double-blind, placebo-controlled study.
(1998). Establishment and characterization of a murine osteosarcoma cell line (LM8) with high metastatic potential to the lung.
(1995). et al.: Adjuvant therapy for osteosarcoma in dogs: results of randomized clinical trials using combined liposome-encapsulated muramyl tripeptide and cisplatin. Clin Cancer Res
(2007). et al.: Identification of a novel pyrazolo[3,4-d] pyrimidine able to inhibit cell proliferation of a human osteogenic sarcoma in vitro and in a xenograft model in mice.
(2004). et al.: STAT3 is constitutively activated and supports cell survival in association with survivin expression in gastric cancer cells. Oncogene
(2005). Frank DA: Identification of a genetic signature of activated signal transducer and activator of transcription 3 in human tumors. Cancer Res
(2004). Hanneman WH: Overexpression of the erbB-2 proto-oncogene in canine osteosarcoma cell lines and tumors. Vet Pathol
(2003). Haura EB: Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells. Oncogene
(2004). Helman LJ: The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med
(2006). JD: STAT3 is activated in a subset of the Ewing sarcoma family of tumours.
(2000). Jr: The role of STATs in transcriptional control and their impact on cellular function. Oncogene
(2008). Kleinerman ES: Targeting Lyn inhibits tumor growth and metastasis in Ewing's sarcoma. Mol Cancer Ther
(2005). Liggitt D: Phase I study of liposome-DNA complexes encoding the interleukin-2 gene in dogs with osteosarcoma lung metastases. Hum Gene Ther
London CA: A novel small molecule Met inhibitor, PF236 exhibits biological activity against canine osteosarcoma.
(2005). London CA: Characterization, expression and function of c-Met in canine spontaneous cancers. Veterinary and Comparative Oncology
(2002). London CA: Inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitors. Blood
(2005). Mechanisms of disease: Insights into the emerging role of signal transducers and activators of transcription in cancer. Nat Clin Pract Oncol
(2006). MV: Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer. Clin Cancer Res
(2007). NJ: Abrogation of signal transducer and activator of transcription 3 reactivation after Src kinase inhibition results in synergistic antitumor effects. Clin Cancer Res
(2001). Overexpression of a dominant-negative signal transducer and activator of transcription 3 variant in tumor cells leads to production of soluble factors that induce apoptosis and cell cycle arrest. Cancer Res
(1989). PE: Therapy for osteosarcoma in dogs with intravenous injection of liposome-encapsulated muramyl tripeptide.
(2008). PK: Design, synthesis, and studies of small molecule STAT3 inhibitors. Bioorg, and Med Chem Lett
(1998). RE: Postirradiation sarcomas in Sprague-Dawley rats. Radiat Res
(2004). Role of STATs as downstream signal transducers in Src family kinase-mediated tumorigenesis. Oncogene
(2000). S: Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis. Clin Cancer Res
(2007). Signal transducer and activator of transcription 3 is involved in cell growth and survival of human rhabdomyosarcoma and osteosarcoma cells.
(2007). Small molecule inhibitors of Stat3 signaling pathway. Curr Cancer Drug Targets
(2002). Smithgall TE: Activation of STAT3 by the Src family kinase Hck requires a functional SH3 domain.
(2000). STAT proteins: novel molecular targets for cancer drug discovery. Oncogene
(2001). Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis. P r o c N a t l A c a d S c i U S A
(2006). Targeting signal-transducer-and-activator-of-transcription-3 for prevention and therapy of cancer: modern target but ancient solution.
(2007). Targeting the cytoplasmic and nuclear functions of signal transducers and activators of transcription 3 for cancer therapy. Clin Cancer Res
(2003). Thamm DH, Radinsky R: c-Met tyrosine kinase receptor expression and function in human and canine osteosarcoma cells. Clin Exp Metastasis
(2003). Tosato G: Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. Blood
(2008). Translation of new cancer treatments from pet dogs to humans. Nat Rev Cancer
(1993). Woods VL Jr: Development of a novel spontaneous metastasis model of human osteosarcoma transplanted orthotopically into bone of athymic mice. Cancer Res